Although the exact mechanisms for the augmentation of nab‐paclitaxel‐based chemotherapy by anti‐MMP9 antibody remain indistinct, these can be correlated with normalization or reduction in tumour vasculature, depletion of tumour stroma enhancing bioavailability of chemotherapy drugs and direct inhibition of ECM degradation leading to antimetastatic effects.26, 39, 40. Here, MMP9 is linked to neoplasm.